CMND · Clearmind Medicine Inc.

This 6-K discloses a material financing event involving both the issuance and near-immediate conversion of convertible promissory notes — a structure that combines elements of debt and equity financing with significant dilutive impact. The $2.7 million note issuance at 90% of face value implies a 10% original issue discount, effectively increasing the cost of capital beyond stated interest (which is not disclosed). The conversion of $2,680,029.60 into 4,466,716 shares establishes an effective conversion price of approximately $0.60 per share, providing a concrete benchmark for share valuation at the time of conversion. As this draw is part of a $10 million committed facility established in September 2025, it signals continued reliance on flexible, non-dilutive-at-issuance (but highly dilutive upon conversion) capital — a pattern common among early-stage biotech firms with limited revenue and high cash burn. The absence of disclosed terms such as interest rate, maturity date, or financial covenants reduces transparency around repayment obligations and potential future liquidity pressure. For investors, the rapid conversion suggests either strong investor confidence in near-term milestones or contractual triggers (e.g., qualified financing, listing, or clinical data) that were met — though none are specified in the filing. This event materially increases the outstanding common share count and may influence future warrant exercises, option dilution, and voting power distribution.